We came across a bullish thesis on Pfizer Inc. on HatedMoats’s Substack. In this article, we will summarize the bulls’ thesis ...

Pfizer (PFE) shares have shown some movement this week, drawing attention for investors evaluating the company’s current position and recent performance. The stock’s slight rebound over the past month ...

Mixed options sentiment in Pfizer (PFE), with shares up 52c, or 2.09%, near $25.68. Options volume relatively light with 73k contracts traded and ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both numbers came in well above expectations, with diluted EPS $0.20 higher than ...

3SBio, a China partner of U.S. drug giant Pfizer, has reached agreements to raise approximately $400 million in a share ...

Wondering if Pfizer is a smart buy at today's price? You are not alone, especially as value-focused investors begin to focus ...

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

Pfizer (NYSE:PFE) shares traded higher in the premarket on Tuesday after the New York-based pharma giant reported better-than-expected financials for Q2 2025 and increased its full-year earnings ...

Healthcare giant Pfizer ( PFE 2.24%) has been offering a high yield for some time. But that hasn't been enough to get investors to buy up the stock. You can see that in its sluggish share price, and ...

Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent ...

Pfizer rises after a study found that the company's new mRNA flu vaccine outperforms traditional shots against predominant strains.